



Somapacitan for treating growth hormone deficiency in people 3 to 17 years

Information for the public Published: 3 June 2025

www.nice.org.uk

Somapacitan (Sogroya) is available on the NHS. It is a possible treatment for growth failure caused by growth hormone deficiency in people 3 to 17 years.

Is this treatment right for me or my child?

Your healthcare professionals should give you clear information, talk with you about your or your child's options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See our webpage on making decisions about your care.

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my or my child's day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment or do not want my child to have the treatment? Are there other treatments available?

Information and support

The NHS webpage on restricted growth may be a good place to find out more.

Child Growth Foundation (020 8995 0257) can give you advice and support.

You can also get support from your local Healthwatch.

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-7031-5